       Document 0963
 DOCN  M9460963
 TI    Cytotoxic anticancer drugs: models and concepts for drug discovery and
       development.
 DT    9406
 AU    Valeriote FA; Corbett TH; Baker LH; Wayne State Univ. Sch. of Medicine,
       Detroit, MI
 SO    Dev Oncol; 68:1-409 1992. Unique Identifier : AIDSLINE ICDB/94699849
 AB    This book presents the proceedings of a symposium, held April 26-28,
       1990, in Detroit, Michigan, on models and concepts for discovery and
       development of cytotoxic anticancer drugs. The papers included covered
       these topics: drug discovery 1990; data display and analysis strategies
       for the NCI disease-oriented in vitro antitumor drug screen; discovery
       of solid-tumor active agents, using a soft agar colony-formation
       disk-diffusion assay; thymidylate synthase inhibition of modified
       quinazoline antifolates; DNA-minor groove binding anticancer agents;
       2-([arylmethyl]amino)-1,3-propanediols--discovery, selection and
       development of four clinical candidates; mechanism-based approaches to
       cancer drug discovery; the role of chemical ecology in discovery and
       bulk production of natural products with anticancer activity; chemical
       approaches to improved radiotherapy; large scale anticancer drug
       screening at Sterling Drug, Inc; are antisense oligonucleotides
       therapeutic agents of the future; supercomputer-aided drug
       design--application in oncology and AIDS; extrachromosomal DNA as a
       target for drug development; prospective evaluation of a predictive
       model for plasma concentration-vs-time profiles of investigational
       anticancer drugs in patients; agent-directed preclinical toxicology for
       antineoplastic drugs; preclinical studies with brequinar sodium, a novel
       anticancer agent; diphtheria toxin-related peptide hormone fusion
       proteins--new toxins with therapeutic potential; anti-growth factor
       receptor antibodies as therapy for cancer; regulation of polyamine
       biosynthetic activity and homeostasis as a novel antiproliferative
       strategy; esperamicin A1 (BMY28175), a novel antitumor agent of the
       diyne-ene class; modified 2-tumor (L1210, colon 38) assay to screen for
       solid-tumor-selective agents; 5-fluorouracil schedule optimization in
       metastatic colorectal cancer; and preclinical antitumor efficacy of
       Taxotere, a Taxol analog, and of RP60475, a new benzopyridoindole.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY  Animal  Antineoplastic
       Agents/ADVERSE EFFECTS/CHEMICAL SYNTHESIS/  PHARMACOKINETICS/THERAPEUTIC
       USE  Cell Division  DNA/DRUG EFFECTS  Diphtheria Toxin  *Drug Design
       Drug Screening Assays, Antitumor  Fluorouracil/THERAPEUTIC USE  Folic
       Acid Antagonists  Homeostasis  Human  Oligonucleotides,
       Antisense/THERAPEUTIC USE  Polyamines/ANTAGONISTS & INHIB
       Radiation-Sensitizing Agents  Radiotherapy  Recombinant Fusion
       Proteins/THERAPEUTIC USE  Taxol/*ANALOGS & DERIVATIVES/THERAPEUTIC USE
       Thymidylate Synthetase/ANTAGONISTS & INHIB  Tumor Cells, Cultured
       MONOGRAPH

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

